Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Breast Neoplasms, Male × Epirubicin × Clear all

Phase

Phase 3 1 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 66 Stomach Neoplasms 8 Triple Negative Breast Neoplasms 7 Carcinoma, Hepatocellular 6 Inflammatory Breast Neoplasms 5 Non-Muscle Invasive Bladder Neoplasms 3 Primary Breast Cancer 2 Pathologic Complete Response 2 Lung Neoplasms 2 Esophageal Neoplasms 2 Carcinoma, Ductal, Breast 2 Urinary Bladder Neoplasms 1 Sarcoma 1 Rhabdomyosarcoma 1 Resectable HER2-positive Breast Cancer 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Ovarian Neoplasms 1 Oesophago-gastric Cancer 1 Neoplasms, Unknown Primary 1 Neoplasms 1 Nasopharyngeal Carcinoma 1 Lymphoma, Large B-Cell, Diffuse 1 Hormone Receptor Positive HER-2 Negative Breast Cancer 1 HER2 Positive Early Breast Cancer 1 Gallbladder Neoplasms 1 Fallopian Tube Neoplasms 1 Epstein-Barr Virus Infections 1 Endometrial Neoplasms 1 Carcinoma, Ovarian Epithelial 1 Breast Neoplasms, Male 1

Interventions

exemestane 3 Paclitaxel 3 Goserelin 3 pegfilgrastim 2 Tamoxifen 2 Leuprolide 2 Letrozole 2 Cyclophosphamide 2 trastuzumab biosimilar HLX02 1 ribociclib 1 Zoledronic Acid 1 Trastuzumab 1 Taxes 1 Radiotherapy 1 Radiosurgery 1 Pyridoxine 1 Prochlorperazine 1 Palonosetron 1 PF-05280014 1 Ontruzant 1 Ogivri 1 Methotrexate 1 Metformin 1 Lapatinib 1 Ibandronic Acid 1 Granisetron 1 Gonadotropin-Releasing Hormone 1 Fluorouracil 1 Fentanyl 1 Everolimus 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00301925 2018-08-08

TACT2

Institute of Cancer Research, United Kingdom

Phase 3 Unknown

Breast Neoplasms, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon ⚡